ALFA Finder| Revenue growth | 31.2% YoY |
|---|---|
| Margins | EBITDA margin compressed to 3.7% from 7.9% YoY. |
| Demand visibility | Early signs of improvement despite Middle East logistics challenges. |
Growth
Revenue grew 31.2% YoY but declined 10.5% QoQ. PAT fell to a loss of ₹40 Mn vs ₹19 Mn loss YoY.
Outlook
Focus on EU/UK NIP/OTF pipeline with 3 approvals secured; CAPA remediation for EU-GMP is largely complete and implemented.
Risks
War in Mid East and logistics challenges impacted QoQ performance. Higher utility and employee costs compressed margins.
Last quarter's promises, checked
Delivered
- CAPA implementation → Substantially completed and implemented (= BEAT)
- EU GMP re-inspection → Conducted May 4-7, 2026 (= BEAT)
- NIP+OTF revenue growth → Tripled YoY to ₹138 Mn (= BEAT)
Partly delivered
- Middle East recovery → Nutra grew 71% YoY but logistics/war risks persist (= PARTIAL)
Missed
- EBITDA margin → Compressed to 3.7% from 12.7% in Q4 (= MISS)
- Revenue trajectory → Declined 10.5% QoQ (= MISS)
- Finance costs → Guided constant but rose 10.3% (= MISS)
Investor Presentation filed with NSE, NSE: ZIMLAB. Summary written with AI assistance from the document.
Zim Laboratories Ltd: key numbers
- Share price
- ₹141.00
- Market cap
- ₹756.6 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 365.3×Sector 43.8×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Investor Presentation: Key Takeaways
Q2 FY27 operating income ₹1,054 Mn (+18.9% YoY), EBITDA ₹77 Mn at 7.3% margin, PAT loss ₹21 Mn. EU-GMP cost base weighs on margins.
Zim Laboratories Q2 FY27 Results: Net Loss of ₹2 Cr, Loss Widens
Zim Laboratories Ltd reported revenue from operations of ₹105.4 Cr (+18.8% YoY) and a net loss of ₹2 Cr for Q2 FY27.
- Key figure
- Net loss ₹2 Cr
Zim Laboratories Board Meeting Date
Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.
Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia
Zim Laboratories Credit Rating
CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.
Zim Laboratories Other Announcement
Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.